Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial

• Patient enrolment has been completed in Cynata’s Phase 2 clinical trial of CYP-001 in acute graft versus host disease. • The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo. • Primary evaluation period expected to complete in March 2026, with results in June 2026. • CYP-00